All In Biotech

Drug Trial Radar · NCT07941479

Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke Patients

Effects of a CB1 Antagonist/Inverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase (RIMOSTROKE-2)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Jan 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Sinfatin S.LIndustry
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of this clinical trial is to assess the effect of rimonabantim on the functional independence in adults who have recently experienced a stroke. The study will enroll 80 participants aged 18 to 75 years who had an stroke 30 to 90 days before enrolment and who have difficulties performing daily activities. Participants will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.The study will also help to learn about the safety of rimonabant.

Conditions

  • Subacute Stroke

Interventions

  • RimonabantDrug

    Rimonabant 5 mg administered orally as one orally disintegrating tablet (ODT) once daily for 90 consecutive days.

  • PlaceboDrug

    Participants will receive one matching placebo orally disintegrating tablet (ODT) once daily for 90 consecutive days. The placebo contains no rimonabant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Barthel Index (BI)Time frame: Baseline and end of follow-up (day 135)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario de Albacete

    Albacete, Albacete, Spain

  • Institut Guttmann

    Badalona, Barcelona, Spain

  • Jiménez Lucena S.L. (CLÍNICA I+TÚ)

    Córdoba, Córdoba, Spain

  • Hospital Los Madroños

    Brunete, Madrid, Spain

  • Hospital Clínico San Carlos (HCSC)

    Madrid, Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.